Kuala Lumpur, Malaysia – The Pharm-D Health Science group of companies, a leading player in the pharmaceutical and nutraceutical industry in Malaysia and Singapore, proudly announces its latest new milestone in its mission to push the boundaries of healthcare innovation, through its biotechnology research and development company Biotenova Sdn Bhd’s latest strategic research partnership with prestigious research university, Universiti Putra Malaysia (UPM).
Guided by the motto “Health for all with Science,” the Group of Companies has continually pushed the boundaries of what is possible within healthcare. This latest research partnership underscores its commitment to innovation and collaboration.
The research collaboration focuses specifically on “The Role of Postbiotics (Lassica K014™) in Inflammatory Skin Disorders.” This research partnership marks an exciting step forward in advancing dermatological research, focusing on the unique properties of Lassica K014™, a patented postbiotic ingredient (PI 2022005512) extracted from Biotenova’s proprietary strain, Lactobacillus plantarum K014.
One of Pharm-D Health Science’s most significant achievements is the development of Lassica K014™, a pioneering microbiological solution that has established itself as a pioneer in the rapidly growing postbiotics market.
Postbiotics are inanimate probiotic cells and functional metabolites produced during fermentation. Since 2019, global interest in postbiotics has surged, positioning Lassica K014™ at the forefront of this trend. This innovative solution not only addresses rising demand but also strengthens Pharm-D’s presence in the natural and wellness-focused sectors.
“This collaboration highlights our unwavering commitment to health science excellence and innovation,” said Mr CC Wong , Group Managing Director of the Pharm-D Health Science group of companies. “We are excited about the possibilities that lie ahead.”
This research project aims to develop treatments for inflammatory skin conditions, such as eczema, psoriasis, and dermatitis. By leveraging the unique properties of postbiotic ingredient Lassica K014™, the collaboration seeks to lead the way in research-driven solutions that enhance patient outcomes and improve lives.
“We’re excited to elevate our research with UPM by exploring how our postbiotics can help alleviate skin disorders like eczema, on top of current conventional treatments. With an estimated 12.6% of Malaysians affected, imagine the impact this breakthrough can have on millions who are suffering from this skin disorder,” according to Mr Rhu Yann Ho, Director of Biotenova Sdn Bhd. “We are hopeful this collaboration will open new doors for innovative microbial solutions in skin condition management.”
Looking to the future, Pharm-D Health Science looks forward to the promising opportunities in store.
